News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Subscribe To Our Newsletter & Stay Updated
